WealthPLAN Partners’s Pacira BioSciences PCRX Stock Holding History

WealthPLAN Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8	Closed	-$321	–	891
2023 Q2	$321	Hold	8	–	–	﹤0.01%	1199
2023 Q1	$326	Buy	+8	New	+$318	﹤0.01%	1266
2016 Q3	–	Sell	-38	Closed	-$1	–	1046
2016 Q2	$1	Buy	+38	New	+$1.87K	﹤0.01%	2584
2015 Q4	$6	Buy	+76	New	+$4.3K	﹤0.01%	1728
2015 Q2	$3K	Sell	38 -262	-87%	-$20.6K	﹤0.01%	370
2015 Q1	$27K	Buy	+300	New	+$30.4K	0.01%	295

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

WealthPLAN Partners's PCRX Position: Q3 2023 in Review

WealthPLAN Partners sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 8 shares — an estimated $321 sold.

WealthPLAN Partners first reported a position in PCRX in Q1 2015 and held it in 6 quarters. The position peaked at $27K in Q1 2015. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

WealthPLAN Partners reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
WealthPLAN Partners sold 8 Pacira BioSciences shares in Q3 2023, an estimated $321.
WealthPLAN Partners first reported a position in Pacira BioSciences in Q1 2015 and held it in 6 quarters.
WealthPLAN Partners's Pacira BioSciences position peaked at $27K in Q1 2015.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.